SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease : results from the COVID-19 Global Rheumatology Alliance provider registry
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: While COVID-19 vaccination prevents severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analysed the clinical characteristics of patients with rheumatic disease who developed breakthrough COVID-19 after vaccination against SARS-CoV-2.
METHODS: We included people partially or fully vaccinated against SARS-CoV-2 who developed COVID-19 between 5 January and 30 September 2021 and were reported to the Global Rheumatology Alliance registry. Breakthrough infections were defined as occurring ≥14 days after completion of the vaccination series, specifically 14 days after the second dose in a two-dose series or 14 days after a single-dose vaccine. We analysed patients' demographic and clinical characteristics and COVID-19 symptoms and outcomes.
RESULTS: SARS-CoV-2 infection was reported in 197 partially or fully vaccinated people with rheumatic disease (mean age 54 years, 77% female, 56% white). The majority (n=140/197, 71%) received messenger RNA vaccines. Among the fully vaccinated (n=87), infection occurred a mean of 112 (±60) days after the second vaccine dose. Among those fully vaccinated and hospitalised (n=22, age range 36-83 years), nine had used B cell-depleting therapy (BCDT), with six as monotherapy, at the time of vaccination. Three were on mycophenolate. The majority (n=14/22, 64%) were not taking systemic glucocorticoids. Eight patients had pre-existing lung disease and five patients died.
CONCLUSION: More than half of fully vaccinated individuals with breakthrough infections requiring hospitalisation were on BCDT or mycophenolate. Further risk mitigation strategies are likely needed to protect this selected high-risk population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
RMD open - 8(2022), 1 vom: 15. Apr. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic agents |
|---|
| Anmerkungen: |
Date Completed 08.04.2022 Date Revised 16.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1136/rmdopen-2021-002187 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339176008 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339176008 | ||
| 003 | DE-627 | ||
| 005 | 20240216232205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/rmdopen-2021-002187 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM339176008 | ||
| 035 | |a (NLM)35387864 | ||
| 035 | |a (PII)e002187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liew, Jean |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease |b results from the COVID-19 Global Rheumatology Alliance provider registry |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2022 | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: While COVID-19 vaccination prevents severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analysed the clinical characteristics of patients with rheumatic disease who developed breakthrough COVID-19 after vaccination against SARS-CoV-2 | ||
| 520 | |a METHODS: We included people partially or fully vaccinated against SARS-CoV-2 who developed COVID-19 between 5 January and 30 September 2021 and were reported to the Global Rheumatology Alliance registry. Breakthrough infections were defined as occurring ≥14 days after completion of the vaccination series, specifically 14 days after the second dose in a two-dose series or 14 days after a single-dose vaccine. We analysed patients' demographic and clinical characteristics and COVID-19 symptoms and outcomes | ||
| 520 | |a RESULTS: SARS-CoV-2 infection was reported in 197 partially or fully vaccinated people with rheumatic disease (mean age 54 years, 77% female, 56% white). The majority (n=140/197, 71%) received messenger RNA vaccines. Among the fully vaccinated (n=87), infection occurred a mean of 112 (±60) days after the second vaccine dose. Among those fully vaccinated and hospitalised (n=22, age range 36-83 years), nine had used B cell-depleting therapy (BCDT), with six as monotherapy, at the time of vaccination. Three were on mycophenolate. The majority (n=14/22, 64%) were not taking systemic glucocorticoids. Eight patients had pre-existing lung disease and five patients died | ||
| 520 | |a CONCLUSION: More than half of fully vaccinated individuals with breakthrough infections requiring hospitalisation were on BCDT or mycophenolate. Further risk mitigation strategies are likely needed to protect this selected high-risk population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a antirheumatic agents | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Gianfrancesco, Milena |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Carly |e verfasserin |4 aut | |
| 700 | 1 | |a Izadi, Zara |e verfasserin |4 aut | |
| 700 | 1 | |a Rush, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Lawson-Tovey, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobsohn, Lindsay |e verfasserin |4 aut | |
| 700 | 1 | |a Ja, Clairissa |e verfasserin |4 aut | |
| 700 | 1 | |a Hyrich, Kimme L |e verfasserin |4 aut | |
| 700 | 1 | |a Gossec, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Strangfeld, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Carmona, Loreto |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Frãzao-Mateus, Elsa |e verfasserin |4 aut | |
| 700 | 1 | |a Bulina, Inita |e verfasserin |4 aut | |
| 700 | 1 | |a Stafford, Frances |e verfasserin |4 aut | |
| 700 | 1 | |a Tufan, Abdurrahman |e verfasserin |4 aut | |
| 700 | 1 | |a Graver, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Yardımcı, Gözde Kübra |e verfasserin |4 aut | |
| 700 | 1 | |a Zepa, Julija |e verfasserin |4 aut | |
| 700 | 1 | |a Al Emadi, Samar |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Abutiban, Fatemah |e verfasserin |4 aut | |
| 700 | 1 | |a Dey, Dfiza |e verfasserin |4 aut | |
| 700 | 1 | |a Katigbak, Genevieve |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufman, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalski, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Martínez, Marco Ulises |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Naomi J |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes-Cordero, Greta |e verfasserin |4 aut | |
| 700 | 1 | |a Salido, Evelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Ellison |e verfasserin |4 aut | |
| 700 | 1 | |a Snow, David |e verfasserin |4 aut | |
| 700 | 1 | |a Sparks, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Wise, Leanna |e verfasserin |4 aut | |
| 700 | 1 | |a Bhana, Suleman |e verfasserin |4 aut | |
| 700 | 1 | |a Gore-Massy, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Grainger, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Hausmann, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Sirotich, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Sufka, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Wallace, Zachary |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Pedro M |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Philip C |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdany, Jinoos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t RMD open |d 2015 |g 8(2022), 1 vom: 15. Apr. |w (DE-627)NLM254089658 |x 2056-5933 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:1 |g day:15 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/rmdopen-2021-002187 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 1 |b 15 |c 04 | ||